Navigation Links
Idenix Reports Results from Two Phase IIb Studies of the,Combination of Valopicitabine and Pegylated Interferon in Hepatitis,C Genotype-1 Patients at the 42nd Annual Meeting of the European,Association for the Study of the Liver

Additional Preclinical Data Presented on Valopicitabine Combined with an Investigational Protease Inhibitor

BARCELONA, Spain, April 12, 2007 /PRNewswire-FirstCall/ -- Idenix Pharmaceuticals, Inc. today announced results from two phase IIb studies of the novel combination of valopicitabine (NM283) and pegylated interferon alfa-2a (Pegasys(R)) in both treatment-naive and treatment- experienced patients infected with the genotype-1 strain of the hepatitis C virus (HCV). These data, as well as preclinical data on the active component of valopicitabine in combination with Schering Plough's investigational protease inhibitor boceprevir (SCH 503034), will be presented at the 42nd Annual Meeting of the European Association for the Study of the Liver (EASL).

Pegylated interferon alfa and ribavirin therapy, the current standard of care, is successful in treating 42 - 46 percent of treatment-naive HCV genotype-1 infected patients.(1,2) For patients who do not achieve successful treatment outcomes with pegylated interferon and ribavirin, there are currently no approved treatment options. New antiviral agents are needed to provide more treatment options for patients infected with HCV genotype-1.

"We have learned a great deal about the treatment of patients with hepatitis C, as well as the safety and efficacy of valopicitabine as a result of these large phase IIb trials," said Douglas L. Mayers, executive vice president and chief medical officer of Idenix Pharmaceuticals. "We remain optimistic about the antiviral activity of the combination of valopicitabine and pegylated interferon observed in various patient populations, and believe that multi-drug combinations will play an important role in the treatment of HCV genotype-1 infected patients. We are now working to define valopicitabine's role in therapy, not only in combination with the current standard of care, but also with other investigational compounds in
'"/>




Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Idenix Announces Data Presentations at the 2007 Digestive Disease Week Meeting
2. Corgenix Reports New Clinical Data Correlating AtherOx Technology With Vascular Disease
3. Cobalis Reports Phase III Trial Results for PreHistin in Seasonal Allergic Rhinitis
4. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
5. Cytos Biotechnology Reports Results from Phase IIa Study with CYT003-QbG10 in Patients Suffering from Atopic Dermatitis
6. Cytokinetics Reports Additional Clinical Trials Data for Ispinesib
7. The European Myeloma Platform Reports New Survival data for Revlimid Presented at the International Myeloma Workshop in Greece
8. Cytochroma Reports Positive Phase I Clinical Data for CTA018 Injection
9. Speedel Reports Successful SPP635 Phase IIa Trial in Hypertension
10. Columbia Laboratories Reports Positive Results from Multi-dose Pharmacokinetic Study of Vaginally-administered Lidocaine
11. CytRx Reports Promising Data from Its Open-Label Extension Clinical Trial of Arimoclomol in ALS
Post Your Comments:
(Date:8/22/2014)... , Aug. 22, 2014   Zacks Equity Research highlights ... of the Day and Panera (Nasdaq: PNRA - Free Report ... Research provides analysis on Amicus Therapeutics (Nasdaq: FOLD - Free ... Shire (Nasdaq: SHPG - Free Report ). Here ... Bull of the Day : The biotech bull ...
(Date:8/22/2014)... 2014  Cannabis Science, Inc. (OTC: CBIS), a ... and related consulting, is pleased to announce its ... conference taking place at the Faculty of Medicine ... October 22, 2014.  The multilingual conference brings together ... health professionals, and patients, to discuss the development ...
(Date:8/21/2014)... Hermann Health System and The University of Texas ... to provide a new level of specialized breast screening at ... Houston area. Starting in ... professional breast radiology services for five of Memorial Hermann,s 10 ... Woodlands , Northeast, Southwest and Sugar Land ...
Breaking Medicine Technology:Epizyme, Panera, Amicus Therapeutics, Sanofi and Shire highlighted as Zacks Bull and Bear of the Day 2Epizyme, Panera, Amicus Therapeutics, Sanofi and Shire highlighted as Zacks Bull and Bear of the Day 3Epizyme, Panera, Amicus Therapeutics, Sanofi and Shire highlighted as Zacks Bull and Bear of the Day 4Epizyme, Panera, Amicus Therapeutics, Sanofi and Shire highlighted as Zacks Bull and Bear of the Day 5Epizyme, Panera, Amicus Therapeutics, Sanofi and Shire highlighted as Zacks Bull and Bear of the Day 6Cannabis Science, Inc. (CBIS) to Sponsor 3rd International Conference on Cannabinoids in Medicine in October 2014 in Strasbourg, France 2Cannabis Science, Inc. (CBIS) to Sponsor 3rd International Conference on Cannabinoids in Medicine in October 2014 in Strasbourg, France 3Memorial Hermann, MD Anderson join forces to provide enhanced breast imaging services throughout the Greater Houston Region 2Memorial Hermann, MD Anderson join forces to provide enhanced breast imaging services throughout the Greater Houston Region 3Memorial Hermann, MD Anderson join forces to provide enhanced breast imaging services throughout the Greater Houston Region 4
... Steve Hoffman, Chief Executive Officer of iJET ... intelligence and business resiliency services, will present information ... Continuity Insights 2011 Management Conference. Introducing a case ... where defects and delays could be life-threatening to ...
... April 5, 2011 Practice Fusion, the fastest ... a $23 million Series B round of financing ... Capital Management and Glynn Capital Management, as well ... The round brings the company,s total funding to ...
Cached Medicine Technology:iJET to Lead Discussion on Supplier Resiliency at Continuity Insights Management Conference 2Founders Fund Leads $23 Million Practice Fusion Financing Round 2Founders Fund Leads $23 Million Practice Fusion Financing Round 3Founders Fund Leads $23 Million Practice Fusion Financing Round 4Founders Fund Leads $23 Million Practice Fusion Financing Round 5
(Date:8/22/2014)... with severe disabilities and multiple chronic conditions are screened ... disabilities or no chronic conditions, a new study has ... women with moderate disabilities or women with only one ... scientist with the Li Ka Shing Knowledge Institute of ... disabilities often have other measures of social vulnerability, such ...
(Date:8/22/2014)... NY (PRWEB) August 22, 2014 Ticket ... Caputo tickets in Kalamazoo, New Orleans, Albuquerque and Rapid ... death, the “Long Island Medium,” Theresa Caputo, allows just that. ... Island. She is part of a close knit family who ... speaking with a spiritual healer, realized she had a chance ...
(Date:8/22/2014)... (PRWEB) August 22, 2014 “Dr. Luciana Show ... Lagana , aka Dr. Luciana, is finding it challenging to ... and while taking care of hundreds of students, so the ... for the show is completed, and she recently entered it ... projects including those of her husband, actor/screenwriter Gregory Graham ...
(Date:8/22/2014)... (ESMO), the leading pan-European organisation representing medical oncology ... individuals receiving the Society,s esteemed annual awards. The ... Joensuu and Peter Boyle on the occasion of ... , Carsten Bokemeyer will receive the ESMO Award ... cancer discovery into real benefit at patient level. ...
(Date:8/22/2014)... difficulties, fainting. Each year approx. 265,000 Danes are acutely ... New research from Aarhus University and Aarhus University Hospital ... as every fourth patient are sent home again ... led to the acute hospitalisation., "Naturally, there is no ... hospital disprove that there is a serious illness. So ...
Breaking Medicine News(10 mins):Health News:Women with severe, chronic health issues are screened for breast cancer less often 2Health News:Theresa Caputo Tickets in Kalamazoo at Wings Stadium, Saenger Theatre in New Orleans, Kiva Auditorium in Albuquerque and Rapid City at Don Barnett Arena Now Available 2Health News:Professor Luciana Lagana Dedicates to Her CSUN Students the “Dr. Luciana Show-Aging and Falling” AOF Festival Nomination (Screening at Krikorian Monrovia Cinema on 08/25) 2Health News:Professor Luciana Lagana Dedicates to Her CSUN Students the “Dr. Luciana Show-Aging and Falling” AOF Festival Nomination (Screening at Krikorian Monrovia Cinema on 08/25) 3Health News:Professor Luciana Lagana Dedicates to Her CSUN Students the “Dr. Luciana Show-Aging and Falling” AOF Festival Nomination (Screening at Krikorian Monrovia Cinema on 08/25) 4Health News:ESMO honors outstanding oncology professionals 2Health News:ESMO honors outstanding oncology professionals 3Health News:Many patients are discharged without a diagnosis 2
... , , SAN FRANCISCO , ... Watson Pharmaceuticals, Inc. (NYSE: WPI ) today announced that it ... to more than $2.7 billion for 2009, compared to 2008, ... meet or exceed the forecast the Company provided in November 2009 ...
... , , MISSION, Kan. , ... administrator, announces the launch of a Third Party Administrator ... put into action under the TPA,s own brand, allowing ... expertise without sacrificing the consultative client connection. Services include ...
... reduced secondary lymphedema in study patients , WEDNESDAY, Jan. ... cancer surgery can be prevented or reduced if patients ... after their operation, a new study suggests. , Secondary ... during treatment -- results in fluid retention and arm ...
... ... product design, precision manufacturing and assembly, and its ability to provide medical components ... ... 13, 2010 -- Airtronics Metal Products, a sheet metal design, engineering ...
... OAKLAND, Calif. , Jan. 13 The nation,s ... relief program to recruit nurse volunteers to provide assistance to ... United announced Tuesday night. , Registered Nurse Response Network sent ... following Hurricane Katrina. RNRN has also sent volunteers to ...
... ... in Salt Lake City and the surrounding region, recently hosted top cataract surgeons from around ... In a live TV event, the surgeons performed free cataract surgery on a group of selected ... ...
Cached Medicine News:Health News:Watson Announces Preliminary Financial Performance for FY 2009 2Health News:Watson Announces Preliminary Financial Performance for FY 2009 3Health News:Watson Announces Preliminary Financial Performance for FY 2009 4Health News:Watson Announces Preliminary Financial Performance for FY 2009 5Health News:New Program Provides COBRA Relief for Third Party Administrators 2Health News:New Program Provides COBRA Relief for Third Party Administrators 3Health News:Therapy May Relieve Breast Cancer Surgery Complication 2Health News:Airtronics Metal Products Earns ISO 13485 Certification 2Health News:Largest RN Union Issues Urgent Call for Nurse Volunteers to Assist Earthquake Ravaged Haiti 2Health News:The Eye Institute of Utah Hosts World Renowned Cataract Surgeons: In Economically Trying Times, Nine Fortunate Patients Receive State of the Art Cataract Lenses 2Health News:The Eye Institute of Utah Hosts World Renowned Cataract Surgeons: In Economically Trying Times, Nine Fortunate Patients Receive State of the Art Cataract Lenses 3
Provides maximum comfort upon insertion through ultra-smooth catheter eyelets--formed with advanced ultrasonic technology....
... in four convenient formats to meet all ... custom draping for any surgical procedure. All ... billowing up. , ,The precision, die-cut holes ... layer is soft against the patient's skin. ...
Convective Air Warming Blankets...
... CSZ safely provides effective air warming therapy ... patented design of our WarmAir® FilteredFlo® blankets, ... which supplies gently moving, clean air that ... contaminants to your patient or staff. All ...
Medicine Products: